A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%%/tobramycin 0.3%% with dexamethasone 0.1%%/tobramycin 0.3%% in the treatment of Chinese patients with blepharokeratoconjunctivitis

By Chen Minjie   Gong Lan   Sun Xinghuai   Gu Yangshun   He Xiangge   Qu Jia   Wang Lili   Zhang Mingzhi   Zhong Xingwu  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 385-394

Informa Healthcare

Access to resources Recommend Favorite

Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers

By Mundorf Thomas K.   Ogawa Takahiro   Inui Noritsugu   Naka Hiroaki   Novack Gary D.   Crockett R. Stephens  

Current Medical Research and Opinion, Vol. 21, Iss. 3, 2005-03 ,pp. : 369-374

Informa Healthcare

Access to resources Recommend Favorite

Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis

By White Eric M.   Macy Jonathan I.   Bateman Kirk M.   Comstock Timothy L.  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 287-296

Informa Healthcare

Access to resources Recommend Favorite

Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study

By Inoue Yuichi   Hirata Koichi   Uchimura Naohisa   Kuroda Kenji   Hattori Nobutaka   Takeuchi Masahiro  

Current Medical Research and Opinion, Vol. 29, Iss. 1, 2013-01 ,pp. : 13-21

Informa Healthcare

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite